JAZZ PHARMACEUTICALS PLC overview

Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting PR Newswire DUBLIN, April 10, 2024 Two oral presentations share results of real-world impact of idiopathic hypersomnia and long-term effectiveness of Epidiolex® (cannabidiol) in treatment-resistant epilepsies Thirteen abstracts underscore Jazz's diverse neuroscience portfolio and pioneering efforts to continue advancing the treatment of serious sleep disorders, rare epilepsy...

Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer PR Newswire DUBLIN, April 2, 2024 Submission based on data from Phase 2b HERIZON-BTC-01 trial, which met its primary endpoint in patients receiving zanidatamab for previously treated HER2-positive biliary tract cancer (BTC) Confirmatory Phase 3 trial in first-line (1L) BTC open for enrollment at multiple global sites DUBLIN , April 2, 2024 /PRNewswire/ --...

Oncology is a tricky sector in which to innovate, but we can start by optimizing existing combination approaches NORTHAMPTON, MA / ACCESSWIRE / March 28, 2024 / Jazz Pharmaceuticals By Liz Henderson Liz Henderson, Sr. Vice President Technical Operations at Jazz Pharmaceuticals discusses pioneering innovation in oncology and the importance of the manufacturing infrastructure to help achieve drug development goals. Originally published by the Medicine Maker Historically, innovation in the...

NORTHAMPTON, MA / ACCESSWIRE / March 20, 2024 / Jazz Pharmaceuticals Originally published by Jazz Pharmaceuticals To mark International Women's Day, JAWS (Jazz Association of Women Supporters), the affinity forum created to promote the advancement and impact of women globally in the innovative biotechnology industry, hosted Jenn Harper, the founder and CEO of Cheekbone Beauty Cosmetics for a fireside chat. This inspirational event focused on Ms. Harper's personal journey, her sustainable,...

NORTHAMPTON, MA / ACCESSWIRE / March 14, 2024 / Jazz Pharmaceuticals Originally published by Jazz Pharmaceuticals on LinkedIn In honor of U.S. Black History Month, JazzSoul, the affinity forum created to support Black employees and their allies and foster inclusive conversations at Jazz, celebrated the many contributions of people from the African diaspora. Over the course of the month, valuable insights and historical perspectives were shared from two vastly different career journeys. One event...

Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024 PR Newswire DUBLIN, March 12, 2024 DUBLIN , March 12, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19 , from 8:00 a.m. to 10:00 a.m. ET , focused on zanidatamab, a differentiated, bispecific antibody in late-stage development with the potential to transform the standard of care in multiple HER2-positive cancers. The webcast will highlight the mechanistic...

Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024 PR Newswire DUBLIN, March 12, 2024 DUBLIN , March 12, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a virtual R&D Day, Tuesday, March 19 , from 8:00 a.m. to 10:00 a.m. ET , focused on zanidatamab, a differentiated, bispecific antibody in late-stage development with the potential to transform the standard of care in multiple HER2-positive cancers. The webcast will highlight the mechanistic...

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance PR Newswire DUBLIN, Feb. 28, 2024 – Total revenues of $3.8 billion in 2023 and $1 billion in 4Q23 – – 27% year-over-year revenue increase from combined key growth drivers: Xywav ® , Epidiolex ® and Rylaze ® – – Oncology revenue surpassed $1 billion in 2023 – – Multiple late-stage pipeline catalysts anticipated in 2024 – – 2024 total revenue guidance...